Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 2 016 DKK -0.15% Market Closed
Market Cap: 129.3B DKK

Genmab A/S
Accounts Payable

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Genmab A/S
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Genmab A/S
CSE:GMAB
Accounts Payable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zealand Pharma A/S
CSE:ZEAL
Accounts Payable
kr243.9m
CAGR 3-Years
89%
CAGR 5-Years
32%
CAGR 10-Years
32%
Ascendis Pharma A/S
NASDAQ:ASND
Accounts Payable
€78.6m
CAGR 3-Years
-3%
CAGR 5-Years
16%
CAGR 10-Years
31%
B
Bavarian Nordic A/S
CSE:BAVA
Accounts Payable
kr1.1B
CAGR 3-Years
42%
CAGR 5-Years
30%
CAGR 10-Years
36%
Bioporto A/S
CSE:BIOPOR
Accounts Payable
kr5.2m
CAGR 3-Years
10%
CAGR 5-Years
19%
CAGR 10-Years
10%
Saniona AB
STO:SANION
Accounts Payable
kr25.1m
CAGR 3-Years
20%
CAGR 5-Years
6%
CAGR 10-Years
14%
No Stocks Found

Genmab A/S
Glance View

In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.

GMAB Intrinsic Value
HIDDEN
Show

See Also

Back to Top